Collecting data on outcomes of stem cell transplants

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to gather baseline and outcome data related to all types of hematopoietic stem cell transplants, including those from bone marrow, peripheral blood, and cord blood. Conducted at Queen Mary Hospital, it focuses on understanding the prognostic factors that influence the outcomes of these transplants. The observational nature of the study allows for the collection of real-world data from adult patients who have undergone allogeneic hematopoietic stem cell transplantation. The findings may help improve future transplant protocols and patient care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patients aged 18 years or older who received allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Exclusion Criteria:

* participant who is unable to give informed consent in a prospective cohort.

Where it's running

• Department of Medicine, Queen Mary Hospital
  Hong Kong, Hong Kong Recruiting
• Queen Mary Hospital, Hong Kong
  Hong Kong, Hong Kong Recruiting

Study contacts

• Principal investigator: Harry HS Gill, MBBS, MD, FRCP, FRCPath — Department of Medicine, the University of Hong Kong
• Study coordinator: Harry HS Gill, MBBS, MD, FRCP, FRCPath
• Email: gillhsh@hku.hk
• Phone: +852 22555859

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Withaferin A to help prevent graft-versus-host disease after stem cell transplant

  This trial tests whether adding standardized Withaferin A to standard GvHD prevention can help people 18 and older with blood cancers who are getting a matched related donor stem cell transplant.

  Recruiting at 2 sites Phase 1/2 Tata Memorial Centre · Navi Mumbai, Maharashtra and 1 other locations · NCT07724873

• Venetoclax plus azacitidine consolidation vs standard chemotherapy before stem cell transplant in high-risk AML

  This study tests whether a venetoclax-containing consolidation helps newly diagnosed high-risk AML patients who have CR/CRi after VA induction to improve outcomes before allo-HSCT.

  Recruiting Phase 2 The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07425782

• Ivosidenib maintenance after allogeneic stem cell transplant for IDH1-mutant AML

  This trial tests whether taking ivosidenib versus a placebo after allogeneic stem cell transplant can prevent relapse in adults with IDH1-mutant AML.

  Recruiting at 7 sites Phase 2 Massachusetts General Hospital · Atlanta, Georgia and 6 other locations · NCT06707493

• Treatment for lung infections in patients with certain viral infections and blood cancers

  This study is testing a new inhalation treatment called PUL-042 to see if it can help people with blood cancers or who have had stem cell transplants recover from lung infections caused by certain viruses.

  Recruiting at 11 sites Phase 2 Pulmotect, Inc. · Duarte, California and 11 other locations · NCT06665100

• Long-term observation of lung injury in children after stem cell transplants

  This study looks at children who have had stem cell transplants to see how often they develop lung problems and how these issues affect their health over time.

  Recruiting at 9 sites Children's Hospital Medical Center, Cincinnati · San Francisco, California and 8 other locations · NCT04098445

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.